foscarnet has been researched along with HIV Infections in 86 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of foscarnet on HIV infection in patients with late-stage HIV disease and multiple drug resistance." | 9.12 | Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance. ( Bossi, P; Boubezari, I; Calvez, V; Canestri, A; Caumes, E; Dominguez, S; Ghosn, J; Katlama, C; Ktorza, N; Marguet, F; Wirden, M, 2006) |
| "The clinical significance of cytomegalovirus (CMV) foscarnet resistance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis." | 9.10 | Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. ( Chou, S; Crumpacker, C; Forman, MS; Jabs, DA; Lurain, NS; Martin, BK; Weinberg, A, 2003) |
| "Acyclovir-resistant herpes simplex virus (HSV) infection is common in immunocompromised patients, but the course of such infection is little known." | 7.80 | Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection. ( Agut, H; Boutolleau, D; Burrel, S; Caumes, E; Epelboin, L; Katlama, C; Regnier, S; Seang, S; Valantin, MA; Voujon, D, 2014) |
| "Foscarnet (FOS) is a pyrophosphate analogue that inhibits both cytomegalovirus (CMV) and human immunodeficiency virus (HIV) replication." | 7.78 | Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection. ( Agut, H; Boutolleau, D; Burrel, S; Canestri, A; Clavel-Osorio, C; Katlama, C; Marcelin, AG; Seang, S; Wirden, M, 2012) |
| "Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir." | 7.71 | Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. ( Bestman-Smith, J; Boivin, G, 2002) |
| "The objective of this study was to investigate the prevalence of resistance of herpes simplex virus to acyclovir and foscarnet." | 7.71 | [In vitro susceptibility study of herpes simplex virus to acyclovir and foscarnet. Are routine susceptibility studies necessary?]. ( Cañizares, A; Guerrero, A; Hellín, T; Losada, I; Martí-Belda, P, 2002) |
| " Administration of foscarnet during two years, recommended as suppressive therapy for a previous cytomegalovirus retinitis, might have caused a sustained reduction in plasma HIV-RNA, contributing to her long-term survival." | 7.69 | [Long term survival in an HIV-immunosuppressed patient treated with foscarnet]. ( Bravo, R; González-Lahoz, J; Mas, A; Moreno, V; Soriano, V, 1996) |
| "Ganciclovir and foscarnet are both effective for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome, but the benefits of either agent given alone are limited." | 7.68 | Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. ( Butler, KM; De Smet, MD; Husson, RN; Jarosinski, P; Lovato, G; Manjunath, K; Montrella, K; Mueller, B; Nussenblatt, RB; Pizzo, PA, 1992) |
| "Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes." | 6.38 | Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. ( Jacobson, MA; O'Donnell, JJ, 1991) |
| "Imiquimod treatment also appeared to delay the time to recurrence of HSV lesions." | 5.38 | Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1. ( Agut, H; Caumes, E; Challine, D; Deback, C; Lascaux, AS; Lévy, Y; Melica, G, 2012) |
| "To evaluate the efficacy of foscarnet on HIV infection in patients with late-stage HIV disease and multiple drug resistance." | 5.12 | Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance. ( Bossi, P; Boubezari, I; Calvez, V; Canestri, A; Caumes, E; Dominguez, S; Ghosn, J; Katlama, C; Ktorza, N; Marguet, F; Wirden, M, 2006) |
| "The clinical significance of cytomegalovirus (CMV) foscarnet resistance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis." | 5.10 | Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. ( Chou, S; Crumpacker, C; Forman, MS; Jabs, DA; Lurain, NS; Martin, BK; Weinberg, A, 2003) |
| " Combination therapy with Interferon-α and ribavirin remains the backbone treatment for chronic hepatitis C; the addition of serine protease inhibitors improves the treatment outcome of patients infected with hepatitis C virus genotype 1." | 4.87 | Antiviral drugs for viruses other than human immunodeficiency virus. ( Razonable, RR, 2011) |
| "Recurrent anogenital herpes simplex virus infections are common in patients with human immunodeficiency virus (HIV), of whom approximately 5% develop resistance to acyclovir." | 3.85 | Surgical excision for recurrent herpes simplex virus 2 (HSV-2) anogenital infection in a patient with human immunodeficiency virus (HIV). ( Arinze, F; Raffanti, S; Shaver, A, 2017) |
| "Acyclovir-resistant herpes simplex virus (HSV) infection is common in immunocompromised patients, but the course of such infection is little known." | 3.80 | Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection. ( Agut, H; Boutolleau, D; Burrel, S; Caumes, E; Epelboin, L; Katlama, C; Regnier, S; Seang, S; Valantin, MA; Voujon, D, 2014) |
| "Foscarnet (FOS) is a pyrophosphate analogue that inhibits both cytomegalovirus (CMV) and human immunodeficiency virus (HIV) replication." | 3.78 | Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection. ( Agut, H; Boutolleau, D; Burrel, S; Canestri, A; Clavel-Osorio, C; Katlama, C; Marcelin, AG; Seang, S; Wirden, M, 2012) |
| "A 7-year-old HIV-infected male with frosted branch angiitis was refractory to induction doses of intravenous ganciclovir and foscarnet over a 2-month period." | 3.71 | Frosted branch angiitis in a child with HIV infection. ( Fine, HF; Murante, BL; Nussenblatt, RB; Robinson, MR; Smith, JA, 2001) |
| "The objective of this study was to investigate the prevalence of resistance of herpes simplex virus to acyclovir and foscarnet." | 3.71 | [In vitro susceptibility study of herpes simplex virus to acyclovir and foscarnet. Are routine susceptibility studies necessary?]. ( Cañizares, A; Guerrero, A; Hellín, T; Losada, I; Martí-Belda, P, 2002) |
| "To determine the prevalence of the in vitro resistance rate of cytomegalovirus (CMV) to gancyclovir (GCV) and foscarnet (FOS) among patients with AIDS and chorioretinitis." | 3.71 | [Cytomegalovirus sensitivity to anti-retroviral agents in patients infected with the human immunodeficiency virus with chorioretinitis in Spain]. ( Cañizares, MA; Casado, JL; González, J; Guerrero, A; Losada, I; Pérez-Elías, MJ; Rubio, R, 2001) |
| "Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir." | 3.71 | Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. ( Bestman-Smith, J; Boivin, G, 2002) |
| ") are discussed, as is the use of imiquimod treatment for genital warts." | 3.69 | International Congress on Chemotherapy. ( Smart, T, 1995) |
| " Administration of foscarnet during two years, recommended as suppressive therapy for a previous cytomegalovirus retinitis, might have caused a sustained reduction in plasma HIV-RNA, contributing to her long-term survival." | 3.69 | [Long term survival in an HIV-immunosuppressed patient treated with foscarnet]. ( Bravo, R; González-Lahoz, J; Mas, A; Moreno, V; Soriano, V, 1996) |
| "An AIDS patient experienced an exacerbation of cytomegalovirus retinitis and was treated with foscarnet." | 3.68 | Foscarnet-induced severe hypomagnesemia and other electrolyte disorders. ( Gearhart, MO; Sorg, TB, 1993) |
| "Ganciclovir and foscarnet are both effective for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome, but the benefits of either agent given alone are limited." | 3.68 | Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. ( Butler, KM; De Smet, MD; Husson, RN; Jarosinski, P; Lovato, G; Manjunath, K; Montrella, K; Mueller, B; Nussenblatt, RB; Pizzo, PA, 1992) |
| "Most foscarnet plasma levels were below the assay limit of detection (33 microM) with only 4/30 levels detectable after D5W and 8/30 after ranitidine." | 2.69 | The effect of increasing gastric pH upon the bioavailability of orally-administered foscarnet. ( Barditch-Crovo, PA; Gambertoglio, J; Hafner, R; Kornhauser, DM; Kuwahara, S; Lietman, PS; Nerhood, LJ; Petty, BG, 1998) |
| "We report a case of acute myelitis in an HIV-infected patient, with sustained HHV-7 DNA amplification in cerebrospinal fluid (CSF) and a favourable response to foscarnet." | 2.53 | Acute myelitis by human herpes virus 7 in an HIV-infected patient. ( Buisán Catevilla, J; Corral, I; Escobar-Villalba, A; Galán, JC; Martínez Ulloa, PL; Monreal Laguillo, E; Pérez Torre, P; Rodríguez-Domínguez, M; Sainz de la Maza, S, 2016) |
| " In patients with renal insufficiency, careful dosage adjustment is mandatory to optimize drug exposure and reduce the risk for adverse events." | 2.41 | Anti-viral drugs in continuous ambulatory peritoneal dialysis (CAPD). ( Deray, G; Issad, B; Izzedine, H; Launay-Vacher, V, 2002) |
| "CMV-related retinal detachment is treated surgically." | 2.40 | Cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. ( Au Eong, KG; Beatty, S; Charles, SJ, 1999) |
| "Penile ulcers are best managed by stopping the infusion until the ulcers heal; they may be prevented by paying careful attention to personal hygiene." | 2.40 | Minimising the dosage-limiting toxicities of foscarnet induction therapy. ( Jayaweera, DT, 1997) |
| " The serious toxicity associated with zidovudine has led researchers to develop safer dosage regimens." | 2.38 | Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease. ( Cersosimo, RJ; Matthews, SJ; Spivack, ML, 1991) |
| "Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes." | 2.38 | Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. ( Jacobson, MA; O'Donnell, JJ, 1991) |
| "The incidence of cytomegalovirus retinitis has decreased significantly since the advent of antiretroviral therapy." | 1.40 | Management of ganciclovir-resistant cytomegalovirus retinitis in HIV infection in the era of antiretroviral therapy. ( Acheson, RW; Adler, H; Brannigan, ET; De Gascun, CF; Duffy, M; Keegan, DJ; Lambert, JS; McSweeney, F, 2014) |
| "Imiquimod treatment also appeared to delay the time to recurrence of HSV lesions." | 1.38 | Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1. ( Agut, H; Caumes, E; Challine, D; Deback, C; Lascaux, AS; Lévy, Y; Melica, G, 2012) |
| " The mean peak concentration in plasma following the intravenous administration of foscarnet (90 mg/kg) was 887." | 1.30 | Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients. ( Gazzard, BG; Higgs, CJ; Lant, AF; Martin-Munley, S; Noormohamed, FH; Youle, MS, 1998) |
| "Foscarnet, an expensive treatment, has serious side effects, especially kidney toxicity." | 1.29 | Kaposi's sarcoma: possible Foscarnet treatment? ( James, JS, 1995) |
| "Among the 861 patients with AIDS treated in our unit from 1991 to 1993, 7 cases involving cytomegalovirus infection of the conus medullaris and/or the cauda equina were studied retrospectively." | 1.29 | [Lesions of the conus medullaris and the cauda equina caused by cytomegalovirus in HIV infection. 7 cases]. ( el Amrani, M; Girard, PM; Gozlan, J; Jacomet, C; Lebrette, MG; Monfort, L; Rozenbaum, W, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 50 (58.14) | 18.2507 |
| 2000's | 23 (26.74) | 29.6817 |
| 2010's | 13 (15.12) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arinze, F | 1 |
| Shaver, A | 1 |
| Raffanti, S | 1 |
| Gonzales Zamora, JA | 1 |
| Espinoza, LA | 1 |
| Adler, H | 1 |
| De Gascun, CF | 1 |
| McSweeney, F | 1 |
| Acheson, RW | 1 |
| Brannigan, ET | 1 |
| Duffy, M | 1 |
| Keegan, DJ | 1 |
| Lambert, JS | 1 |
| Seang, S | 2 |
| Boutolleau, D | 2 |
| Burrel, S | 2 |
| Regnier, S | 1 |
| Epelboin, L | 1 |
| Voujon, D | 1 |
| Valantin, MA | 1 |
| Katlama, C | 5 |
| Agut, H | 3 |
| Caumes, E | 5 |
| Leporrier, J | 1 |
| Etienne, M | 1 |
| Chapuzet, C | 1 |
| Peytavin, G | 2 |
| Bord, S | 1 |
| Borsa-Lebas, F | 1 |
| Caron, F | 1 |
| Plantier, JC | 1 |
| Mourez, T | 1 |
| Delory, T | 1 |
| Papot, E | 1 |
| Rioux, C | 1 |
| Charpentier, C | 3 |
| Auge-Courtoi, C | 1 |
| Michard, F | 1 |
| Descamps, D | 1 |
| Matheron, S | 1 |
| Yazdanpanah, Y | 1 |
| Escobar-Villalba, A | 1 |
| Sainz de la Maza, S | 1 |
| Pérez Torre, P | 1 |
| Galán, JC | 1 |
| Rodríguez-Domínguez, M | 1 |
| Monreal Laguillo, E | 1 |
| Martínez Ulloa, PL | 1 |
| Buisán Catevilla, J | 1 |
| Corral, I | 1 |
| Kisic, M | 1 |
| Mendieta, J | 1 |
| Puertas, MC | 1 |
| Parera, M | 1 |
| Martínez, MA | 1 |
| Martinez-Picado, J | 1 |
| Menéndez-Arias, L | 1 |
| Laureillard, D | 2 |
| Sodqi, M | 1 |
| Si-Mohamed, A | 2 |
| Karmochkine, M | 2 |
| Bélec, L | 1 |
| Weiss, L | 2 |
| Piketty, C | 2 |
| Yudin, MH | 1 |
| Kaul, R | 1 |
| Sohal, A | 1 |
| Riordan, A | 1 |
| Mallewa, M | 1 |
| Solomon, T | 1 |
| Kneen, R | 1 |
| Stegmann, S | 1 |
| Manea, ME | 1 |
| Damond, F | 1 |
| Tan, DH | 1 |
| Walmsley, SL | 1 |
| Ridha, E | 1 |
| Cookson, H | 1 |
| Devitt, E | 1 |
| Nelson, M | 1 |
| Razonable, RR | 1 |
| Lascaux, AS | 1 |
| Deback, C | 1 |
| Melica, G | 1 |
| Challine, D | 1 |
| Lévy, Y | 1 |
| Canestri, A | 2 |
| Wirden, M | 2 |
| Clavel-Osorio, C | 1 |
| Marcelin, AG | 1 |
| Weinberg, A | 1 |
| Jabs, DA | 1 |
| Chou, S | 1 |
| Martin, BK | 1 |
| Lurain, NS | 1 |
| Forman, MS | 1 |
| Crumpacker, C | 1 |
| Money, DM | 1 |
| Mathiesen, S | 2 |
| Roge, BT | 1 |
| Weis, N | 1 |
| Lundgren, JD | 1 |
| Obel, N | 1 |
| Gerstoft, J | 2 |
| Tanaka-Taya, K | 1 |
| Ghislanzoni, M | 1 |
| Cusini, M | 1 |
| Zerboni, R | 1 |
| Alessi, E | 1 |
| Ghosn, J | 1 |
| Marguet, F | 1 |
| Ktorza, N | 1 |
| Boubezari, I | 1 |
| Dominguez, S | 1 |
| Bossi, P | 1 |
| Calvez, V | 1 |
| Dam, E | 1 |
| Roge, B | 1 |
| Joergensen, LB | 1 |
| Laursen, AL | 1 |
| Clavel, F | 1 |
| Caliendo, AM | 1 |
| Hirsch, MS | 1 |
| Mellors, JW | 1 |
| Bazmi, HZ | 1 |
| Schinazi, RF | 1 |
| Roy, BM | 1 |
| Hsiou, Y | 1 |
| Arnold, E | 1 |
| Weir, J | 1 |
| Mayers, DL | 1 |
| Vela Moreno, J | 1 |
| Pascual Catalán, A | 1 |
| Ramos Paesa, C | 1 |
| Arazo Garcés, P | 1 |
| Aguirre Errasti, JM | 1 |
| Morfeldt, L | 1 |
| Torssander, J | 1 |
| Jacomet, C | 1 |
| Lebrette, MG | 1 |
| el Amrani, M | 1 |
| Monfort, L | 1 |
| Gozlan, J | 1 |
| Girard, PM | 1 |
| Rozenbaum, W | 1 |
| Fletcher, CV | 1 |
| Collier, AC | 1 |
| Rhame, FS | 1 |
| Bennett, D | 1 |
| Para, MF | 1 |
| Beatty, CC | 1 |
| Jones, CE | 1 |
| Balfour, HH | 1 |
| Stamminger, T | 1 |
| Fleckenstein, B | 1 |
| Safrin, S | 1 |
| Elbeik, T | 1 |
| Phan, L | 1 |
| Robinson, D | 1 |
| Rush, J | 1 |
| Elbaggari, A | 1 |
| Mills, J | 2 |
| Freeman, WR | 2 |
| Leport, C | 1 |
| Puget, S | 1 |
| Pepin, JM | 1 |
| Levy, S | 1 |
| Perronne, C | 1 |
| Brun-Vezinet, F | 1 |
| Vildé, JL | 1 |
| Friedberg, DN | 1 |
| Berry, C | 1 |
| Quiceno, JI | 1 |
| Behette, M | 1 |
| Fullerton, SC | 1 |
| Munguia, D | 1 |
| Baumann, R | 1 |
| Wunderli, W | 1 |
| Riess, C | 1 |
| Vogt, M | 1 |
| Heinic, GS | 1 |
| Greenspan, D | 1 |
| Greenspan, JS | 1 |
| Gearhart, MO | 1 |
| Sorg, TB | 1 |
| Gatineau, M | 1 |
| Bricaire, F | 2 |
| Dohin, E | 1 |
| Gentilini, M | 1 |
| Giezendanner, S | 1 |
| Wirth, HP | 1 |
| Zala, G | 1 |
| Weber, R | 1 |
| Flury, R | 1 |
| Meyenberger, C | 1 |
| Hoover, DR | 1 |
| Peng, Y | 1 |
| Saah, A | 1 |
| Semba, R | 1 |
| Detels, RR | 1 |
| Rinaldo, CR | 1 |
| Phair, JP | 1 |
| Danner, SA | 1 |
| Mocroft, A | 1 |
| Youle, M | 1 |
| Gazzard, B | 1 |
| Morcinek, J | 1 |
| Halai, R | 1 |
| Phillips, AN | 1 |
| Soriano, V | 1 |
| Mas, A | 1 |
| Bravo, R | 1 |
| Moreno, V | 1 |
| González-Lahoz, J | 1 |
| Segondy, M | 1 |
| Montes, B | 1 |
| Delmas, B | 1 |
| Leclercq, C | 1 |
| Janbon, F | 1 |
| Reynes, J | 1 |
| Quartier, P | 1 |
| Khouri, J | 1 |
| Maout, F | 1 |
| Courpotin, C | 1 |
| Dollfus, C | 1 |
| Tabone, MD | 1 |
| Leverger, G | 1 |
| Lasfargues, G | 1 |
| Mallolas, J | 1 |
| Gatell, JM | 1 |
| Gómez-Sirvent, JL | 1 |
| Buira, E | 1 |
| Zamora, L | 1 |
| Alecrim-Andrade, J | 1 |
| Adán, A | 1 |
| Morales, M | 1 |
| Miró, JM | 1 |
| Lonća, M | 1 |
| Guelar, A | 1 |
| Soriano, E | 1 |
| Jayaweera, DT | 1 |
| Nakano, T | 1 |
| Morozumi, H | 1 |
| Inuzuka, S | 1 |
| Nagata, M | 1 |
| Taguchi, Y | 1 |
| Mizokami, M | 1 |
| Okamoto, T | 1 |
| Palmer, S | 1 |
| Alaeus, A | 1 |
| Albert, J | 1 |
| Cox, S | 1 |
| Noormohamed, FH | 1 |
| Youle, MS | 1 |
| Higgs, CJ | 1 |
| Martin-Munley, S | 1 |
| Gazzard, BG | 1 |
| Lant, AF | 1 |
| Barditch-Crovo, PA | 1 |
| Petty, BG | 1 |
| Gambertoglio, J | 1 |
| Nerhood, LJ | 1 |
| Kuwahara, S | 1 |
| Hafner, R | 2 |
| Lietman, PS | 1 |
| Kornhauser, DM | 1 |
| Breton, G | 1 |
| Fillet, AM | 1 |
| Boivin, G | 2 |
| Gaudreau, A | 1 |
| Toma, E | 1 |
| Lalonde, R | 1 |
| Routy, JP | 1 |
| Murray, G | 1 |
| Handfield, J | 1 |
| Bergeron, MG | 1 |
| Iten, A | 1 |
| Chatelard, P | 1 |
| Vuadens, P | 1 |
| Miklossy, J | 1 |
| Meuli, R | 1 |
| Sahli, R | 1 |
| Meylan, PR | 1 |
| Rabkin, CS | 1 |
| Testa, MA | 1 |
| Huang, J | 1 |
| Von Roenn, JH | 1 |
| Walmsley, S | 1 |
| Tseng, A | 1 |
| Parra Ródenas, JV | 1 |
| Riera Ayora, M | 1 |
| Ronda Gasulla, A | 1 |
| Herrera Ballester, A | 1 |
| Nikkels, AF | 1 |
| Snoeck, R | 1 |
| Rentier, B | 1 |
| Pierard, GE | 1 |
| Willers, CP | 1 |
| Reimann, G | 1 |
| Mertins, L | 1 |
| Brockmeyer, NH | 1 |
| Au Eong, KG | 1 |
| Beatty, S | 1 |
| Charles, SJ | 1 |
| Schmidt, W | 1 |
| Anagnostopoulos, I | 1 |
| Scherübl, H | 1 |
| MacMahon, EM | 1 |
| Jones, JL | 1 |
| Hanson, DL | 1 |
| Dworkin, MS | 1 |
| Jaffe, HW | 1 |
| Schramm, C | 1 |
| Schlaak, JF | 1 |
| Galle, PR | 1 |
| Fine, HF | 1 |
| Smith, JA | 1 |
| Murante, BL | 1 |
| Nussenblatt, RB | 2 |
| Robinson, MR | 1 |
| James, JS | 1 |
| Smart, T | 1 |
| Ball, SC | 1 |
| Losada, I | 2 |
| Cañizares, A | 1 |
| Hellín, T | 1 |
| Martí-Belda, P | 1 |
| Guerrero, A | 2 |
| Cañizares, MA | 1 |
| Pérez-Elías, MJ | 1 |
| González, J | 1 |
| Rubio, R | 1 |
| Casado, JL | 1 |
| Aoki, FY | 1 |
| Bestman-Smith, J | 1 |
| Izzedine, H | 1 |
| Launay-Vacher, V | 1 |
| Issad, B | 1 |
| Deray, G | 1 |
| Butler, KM | 1 |
| De Smet, MD | 1 |
| Husson, RN | 1 |
| Mueller, B | 1 |
| Manjunath, K | 1 |
| Montrella, K | 1 |
| Lovato, G | 1 |
| Jarosinski, P | 1 |
| Pizzo, PA | 1 |
| Jacobson, MA | 2 |
| Molina, JM | 1 |
| David, F | 1 |
| Scieux, C | 1 |
| Schnell, L | 1 |
| Gerrier, F | 1 |
| Kateb, M | 1 |
| Morinet, F | 1 |
| Modai, J | 1 |
| Smith, KJ | 1 |
| Kahlter, DC | 1 |
| Davis, C | 1 |
| James, WD | 1 |
| Skelton, HG | 1 |
| Angritt, P | 1 |
| Matthews, SJ | 1 |
| Cersosimo, RJ | 1 |
| Spivack, ML | 1 |
| Jacobsen, MA | 1 |
| van der Horst, C | 1 |
| Causey, DM | 1 |
| Dehlinger, M | 1 |
| O'Donnell, JJ | 1 |
| Henderly, DE | 1 |
| Jampol, LM | 1 |
| Cotton, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease[NCT00000729] | Phase 1 | 10 participants | Interventional | Completed | |||
| The Effect of Increasing Gastric pH Upon the Bioavailability of Orally Administered Phosphonoformic Acid (Foscarnet)[NCT00000964] | Phase 1 | 6 participants | Interventional | Completed | |||
| A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China[NCT02151240] | Phase 4 | 94 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Intermittent Foscarnet Therapy for Human Immunodeficiency Virus Infection in Patients Receiving Long-Term Zidovudine Therapy[NCT00001002] | Phase 1 | 12 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 reviews available for foscarnet and HIV Infections
| Article | Year |
|---|---|
Acute myelitis by human herpes virus 7 in an HIV-infected patient.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; DNA, Viral; Foscarnet; Herpesvirus 7, Hu | 2016 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; | 2011 |
Antiviral and antiretroviral use in pregnancy.
Topics: Animals; Anti-Retroviral Agents; Antiviral Agents; Enzyme Inhibitors; Female; Foscarnet; HIV Infecti | 2003 |
[Human cytomegalovirus infection].
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; gamma-Globulins; Ganciclov | 2005 |
Combination therapy for infection due to human immunodeficiency virus type 1.
Topics: Acyclovir; Antiviral Agents; CD4 Antigens; Clinical Trials as Topic; Combined Modality Therapy; Dida | 1994 |
Retinal disease associated with AIDS.
Topics: AIDS-Related Opportunistic Infections; CD4-Positive T-Lymphocytes; Cytomegalovirus Infections; Eye I | 1993 |
Oral CMV lesions and the HIV infected. Early recognition can help prevent morbidity.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarnet; Ganciclovir; HIV Infec | 1993 |
Management of cytomegalovirus disease.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Therapy, Combination; Foscar | 1995 |
Minimising the dosage-limiting toxicities of foscarnet induction therapy.
Topics: Animals; Antiviral Agents; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Female; Fos | 1997 |
Comparative tolerability of therapies for cytomegalovirus retinitis.
Topics: Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; Ganciclovir; HIV Infections; Humans | 1999 |
Chronic verrucous varicella zoster virus skin lesions: clinical, histological, molecular and therapeutic aspects.
Topics: Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarnet; Herpesvirus 3, Human; HIV Infect | 1999 |
Cytomegalovirus retinitis in patients with acquired immune deficiency syndrome.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Foscarnet; Ga | 1999 |
Persistent herpes simplex virus infection.
Topics: Acyclovir; Adult; Female; Foscarnet; Herpes Labialis; HIV Infections; Humans; Immunocompromised Host | 2001 |
Management of genital herpes in HIV-infected patients.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral A | 2001 |
Anti-viral drugs in continuous ambulatory peritoneal dialysis (CAPD).
Topics: Adamantane; Anti-HIV Agents; Antimetabolites; Antiviral Agents; Dideoxynucleosides; Foscarnet; Hepat | 2002 |
Foscarnet therapy for AIDS-related opportunistic herpesvirus infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Comb | 1992 |
Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Female; Foscarnet; H | 1991 |
Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Combination; Eye Infections, Viral; Fosc | 1991 |
Diagnosis and treatment of cytomegalovirus retinitis.
Topics: Antiviral Agents; Cytomegalovirus Infections; Diagnosis, Differential; Eye Infections, Viral; Foscar | 1991 |
6 trials available for foscarnet and HIV Infections
| Article | Year |
|---|---|
Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cohort Studies; Cytomegalovirus; Cyt | 2003 |
Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.
Topics: Adult; Aged; CD4 Lymphocyte Count; Disease Progression; Drug Resistance, Multiple, Viral; Foscarnet; | 2006 |
Foscarnet for suppression of human immunodeficiency virus replication.
Topics: Adult; Bayes Theorem; CD4-Positive T-Lymphocytes; Double-Blind Method; Female; Foscarnet; HIV Antige | 1994 |
Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group.
Topics: Acyclovir; Adolescent; Adult; Aged; Antiviral Agents; Disease Progression; Female; Follow-Up Studies | 1996 |
[Prophylaxis secondary to retinitis by CMV in patients with AIDS: the efficacy of an intermittent schedule of 3 days/week].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Admi | 1997 |
The effect of increasing gastric pH upon the bioavailability of orally-administered foscarnet.
Topics: Administration, Oral; Antiviral Agents; Biological Availability; Chromatography, High Pressure Liqui | 1998 |
61 other studies available for foscarnet and HIV Infections
| Article | Year |
|---|---|
Surgical excision for recurrent herpes simplex virus 2 (HSV-2) anogenital infection in a patient with human immunodeficiency virus (HIV).
Topics: Acyclovir; Antiviral Agents; Drug Resistance, Viral; Foscarnet; Herpes Genitalis; Herpesvirus 2, Hum | 2017 |
Verrucous herpes of the finger in a patient with HIV-1 infection.
Topics: Acyclovir; Administration, Intravenous; Administration, Oral; Antiviral Agents; Fingers; Foscarnet; | 2018 |
Management of ganciclovir-resistant cytomegalovirus retinitis in HIV infection in the era of antiretroviral therapy.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; HIV I | 2014 |
Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytosine; Drug | 2014 |
Association of dolutegravir and rilpivirine, enhanced by foscarnet induction, in effective salvage antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Foscarnet; He | 2014 |
Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2016 |
Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.
Topics: Amino Acid Sequence; Anti-HIV Agents; Codon; Crystallography, X-Ray; Deoxycytosine Nucleotides; DNA, | 2008 |
Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Foscarnet; HIV In | 2008 |
Progressive hypertrophic genital herpes in an HIV-infected woman despite immune recovery on antiretroviral therapy.
Topics: Administration, Topical; Adult; AIDS-Related Opportunistic Infections; Aminoquinolines; Antineoplast | 2008 |
Successful treatment of cytomegalovirus polyradiculopathy in a 9-year-old child with congenital human immunodeficiency virus infection.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Brain; Child; Cytomegalovirus Infections; D | 2009 |
Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure.
Topics: Foscarnet; HIV Infections; HIV-2; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, | 2010 |
Response to Stegmann s, et Al. [J. Clin. Virol. 47 (1) (2010) 79-81].
Topics: Anti-HIV Agents; Foscarnet; HIV Infections; HIV-2; Humans; Salvage Therapy; Treatment Outcome; Viral | 2010 |
Febrile neutropenia in a HIV positive individual post-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Cytomegalovirus | 2010 |
Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1.
Topics: Acyclovir; Administration, Topical; Adult; Aminoquinolines; Antiviral Agents; Drug Resistance, Viral | 2012 |
Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 2012 |
Accelerated development of viral inhibitor Thirovir for HIV.
Topics: Administration, Oral; Anti-HIV Agents; Drug Approval; Foscarnet; HIV Infections; Humans; Virus Repli | 2003 |
Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Multiple, Viral; Foscarnet; HIV Infections; | 2004 |
Chronic hypertrophic acyclovir-resistant genital herpes treated with topical cidofovir and with topical foscarnet at recurrence in an HIV-positive man.
Topics: Acyclovir; Administration, Topical; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chronic | 2006 |
Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Multiple, Viral; Evolution, Molecular; Fo | 2007 |
Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.
Topics: Base Sequence; Cells, Cultured; Cloning, Molecular; DNA, Viral; Foscarnet; HIV Infections; HIV Rever | 1995 |
[Tetany caused by foscarnet in a female patient with acquired immunodeficiency syndrome].
Topics: Adult; Antiviral Agents; Female; Foscarnet; HIV Infections; Humans; Tetany | 1995 |
Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients.
Topics: Adult; Foscarnet; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Palatal Neoplasms; | 1994 |
[Lesions of the conus medullaris and the cauda equina caused by cytomegalovirus in HIV infection. 7 cases].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Cauda Equina; Cyto | 1995 |
[Current developments in antiviral chemotherapy. Part 4: Foscarnet, zidovudine, didanosine].
Topics: AIDS-Related Opportunistic Infections; Didanosine; Dose-Response Relationship, Drug; Drug Administra | 1994 |
Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients.
Topics: Acyclovir; Female; Foscarnet; Herpes Simplex; HIV Infections; Humans; Male; Microbial Sensitivity Te | 1994 |
Cytomegalovirus resistant to foscarnet: clinicovirologic correlation in a patient with human immunodeficiency virus.
Topics: Cytomegalovirus; Cytomegalovirus Retinitis; Drug Resistance, Microbial; Foscarnet; Ganciclovir; HIV | 1993 |
Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Follow-Up Studies; Foscarnet; Ganc | 1993 |
[Acyclovir-resistant Herpes simplex viruses in HIV-infected patients].
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Drug Resistance, Microbial; Female; Foscarn | 1993 |
Foscarnet-induced severe hypomagnesemia and other electrolyte disorders.
Topics: Adult; Cytomegalovirus Infections; Foscarnet; HIV Infections; Hospitals, Community; Hospitals, Teach | 1993 |
Foscarnet-induced vulvar erosion.
Topics: Adult; Female; Foscarnet; HIV Infections; Humans; Retinal Necrosis Syndrome, Acute; Ulcer; Vulvar Di | 1993 |
[Clinical manifestations and course of cytomegalovirus colitis in AIDS patients].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cohort Studies; Colitis; Colonoscopy | 1995 |
Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lympho | 1996 |
[Long term survival in an HIV-immunosuppressed patient treated with foscarnet].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Cytomegaloviru | 1996 |
Changes in HIV-1 RNA plasma level in patients treated with foscarnet.
Topics: Anti-HIV Agents; Cytomegalovirus Retinitis; Foscarnet; HIV Infections; HIV-1; Humans; RNA, Viral | 1997 |
[Early diagnosis and treatment of cytomegalovirus polyradiculoneuritis in a child infected by HIV].
Topics: AIDS-Related Opportunistic Infections; Child; Cytomegalovirus Infections; Drug Therapy, Combination; | 1996 |
Clonal selection of HIV type 1 variants associated with resistance to foscarnet in vitro: confirmation by molecular evolutionary analysis.
Topics: Amino Acid Sequence; Anti-HIV Agents; Arginine; Biological Evolution; Cells, Cultured; Cloning, Mole | 1997 |
Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.
Topics: Anti-HIV Agents; Cell Line, Transformed; Cells, Cultured; Didanosine; Foscarnet; HIV Infections; HIV | 1998 |
Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients.
Topics: Administration, Oral; Adult; Antiviral Agents; Biological Availability; Foscarnet; HIV; HIV Infectio | 1998 |
Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Drug Res | 1998 |
Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganc | 1999 |
Impact of cerebrospinal fluid PCR on the management of HIV-infected patients with varicella-zoster virus infection of the central nervous system.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Central Nervous System In | 1999 |
Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; | 1999 |
[Lumbosacral and meningeal polyradicular disease in a patient with HIV infection].
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Antiviral Agents; Brain; Cytome | 1999 |
Influence of foscarnet on HIV-associated Kaposi's sarcoma derived cell lines.
Topics: Antiviral Agents; Cell Division; Fibroblasts; Foscarnet; Herpesvirus 8, Human; HIV Infections; Human | 1999 |
Virostatic therapy for advanced lymphoproliferation associated with the Epstein-Barr virus in an HIV-infected patient.
Topics: Adult; Antiviral Agents; Burkitt Lymphoma; Foscarnet; Herpesvirus 4, Human; HIV Infections; Humans; | 2000 |
More on virostatic therapy for advanced lymphoproliferation associated with Epstein-Barr virus in an HIV-infected patient.
Topics: Anti-HIV Agents; Antiviral Agents; Burkitt Lymphoma; Foscarnet; Herpesvirus 4, Human; HIV Infections | 2000 |
Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Drug Therapy, Combination; | 2000 |
Rapid development of Epstein-Barr virus-associated Hodgkin's disease after cessation of foscarnet therapy in an HIV-infected patient.
Topics: Antiviral Agents; Epstein-Barr Virus Infections; Foscarnet; HIV Infections; Hodgkin Disease; Humans; | 2000 |
Frosted branch angiitis in a child with HIV infection.
Topics: Antiviral Agents; Child; Cytomegalovirus Retinitis; Foscarnet; Ganciclovir; Glucocorticoids; HIV Inf | 2001 |
Kaposi's sarcoma: possible Foscarnet treatment?
Topics: Foscarnet; HIV Infections; Humans; Sarcoma, Kaposi | 1995 |
New drug applications sought.
Topics: AIDS-Related Opportunistic Infections; Clarithromycin; Cytomegalovirus Retinitis; Drug Approval; Dru | 1995 |
International Congress on Chemotherapy.
Topics: Adjuvants, Immunologic; AIDS-Related Opportunistic Infections; Aminoquinolines; Anti-Bacterial Agent | 1995 |
Herpes study and resources.
Topics: 2-Aminopurine; Acyclovir; Adult; Antiviral Agents; Biopolymers; Catechin; Clinical Trials as Topic; | 1997 |
[In vitro susceptibility study of herpes simplex virus to acyclovir and foscarnet. Are routine susceptibility studies necessary?].
Topics: Acyclovir; Antiviral Agents; Diagnostic Tests, Routine; Drug Resistance, Viral; Foscarnet; Herpes Si | 2002 |
[Cytomegalovirus sensitivity to anti-retroviral agents in patients infected with the human immunodeficiency virus with chorioretinitis in Spain].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Chorioretinitis; Cytomegalovirus; Cy | 2001 |
Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy.
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Foscarnet; Herpes Genitalis; Herpes | 2002 |
Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus.
Topics: Antiviral Agents; Child, Preschool; Cytomegalovirus Infections; Drug Therapy, Combination; Female; F | 1992 |
[Type 1 herpesvirus cutaneo-mucous infection resistant to aciclovir in a HIV infected patient. Clinical and virological study].
Topics: Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; Foscarnet; Herpes Simplex; HIV Infec | 1992 |
Acyclovir-resistant varicella zoster responsive to foscarnet.
Topics: Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; Foscarnet; Herpes Zoster; Herpesviru | 1991 |
In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG Protocol 053).
Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Foscarnet; Gen | 1991 |
Wider access provided to AIDS drugs with actions against HIV, CMV infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV Inf | 1990 |